10-Q: MaxCyte Reports Second Quarter 2024 Financial Results, Revenue Driven by Strategic Partnerships

MaxCyte's second quarter 2024 results show a revenue increase driven by strategic platform licenses, despite a decrease in core revenue.

Summary

• MaxCyte reported a total revenue of $10.4 million for the three months ended June 30, 2024, a 15% increase compared to $9.0 million in the same period of 2023.
• The increase in revenue was primarily driven by a significant rise in program-related revenue, which reached $2.9 million, a 279% increase year-over-year.
• Core revenue, which includes sales and leases of instruments and disposables, decreased by 9% to $7.6 million.
• The company's gross profit for the quarter was $8.9 million, with a gross margin of 86%, compared to 85% in the prior year.
• Operating expenses totaled $20.9 million, with a net loss of $9.4 million for the quarter.
• For the six months ended June 30, 2024, total revenue was $21.8 million, a 24% increase compared to $17.6 million in the same period of 2023.
• The company's net loss for the six months ended June 30, 2024 was $18.9 million.
• As of June 30, 2024, MaxCyte had cash and cash equivalents of $37.5 million and an accumulated deficit of $194.7 million.

Sentiment

Score: 6

Explanation: The document shows positive revenue growth driven by strategic partnerships, but this is offset by a decrease in core revenue and continued net losses. The company is investing in growth, but faces risks and uncertainties. The sentiment is cautiously optimistic.

Positives

• Program-related revenue saw a significant increase, indicating successful progress in strategic partnerships.
• The company's gross margin remained strong at 86% for the quarter and 87% for the six month period.
• MaxCyte secured five new strategic platform license agreements in the first half of 2024, expanding its partnership network.
• Total revenue increased by 24% for the six months ended June 30, 2024, demonstrating overall growth.

Negatives

• Core revenue decreased by 9% for the three months ended June 30, 2024, driven by decreases in instrument and disposable sales.
• The company continues to experience net losses, with a net loss of $9.4 million for the quarter and $18.9 million for the six month period.
• Operating expenses remain high, totaling $20.9 million for the quarter and $43.1 million for the six month period.

Risks

• The company's revenue is subject to variability due to the timing of product sales, licenses, and the achievement of milestones by partners.
• The market for non-viral delivery is highly competitive, and new entrants could negatively impact MaxCyte's business and pricing.
• The company's ability to achieve profitability depends on the successful commercialization and market acceptance of its products.
• The company's future funding requirements will depend on various factors, and additional financing may be needed.
• The company has an accumulated deficit of $194.7 million as of June 30, 2024.

Future Outlook

The company expects total revenue to increase over time as customer programs advance and markets grow, resulting in additional instrument sales and leases, disposable sales, and an increase in the percentage of the installed base under cell therapy license agreements. The company also expects revenue from disposable and instrument sales and instrument licenses to cell therapy customers to continue to grow as those customers advance their preclinical pipeline programs into clinical development and move their existing drug development programs into later-stage clinical trials and, potentially, into commercialization. However, the company expects that revenue may fluctuate from period to period due to the timing of securing product sales and licenses, the inherently uncertain nature of the timing of partners' achievements of clinical progress, and the company's dependence on the program decisions of its partners.

Management Comments

• The company continues to grow its SPL pipeline and looks forward to building on existing SPL partnerships and developing additional SPL partnerships in the future.
• The company believes it is well positioned to attract new customers based on the underlying growth in the cell therapy pipeline among companies in this market, the extent to which capital is available to support such companies, and in particular the switch by some cell therapy companies away from viral to non-viral approaches.

Industry Context

MaxCyte operates in the rapidly expanding cell therapy market, providing enabling platform technologies for the discovery, development, and commercialization of next-generation cell therapeutics. The company's technology is used by biopharmaceutical companies to facilitate complex engineering of a wide variety of cells. The company's strategic platform licenses are a key driver of revenue growth, reflecting the increasing adoption of its technology in the cell therapy sector. The company is also benefiting from a shift in the industry towards non-viral delivery approaches, which aligns with its core technology.

Comparison to Industry Standards

• MaxCyte's revenue growth is driven by its strategic platform licenses, which is a unique model compared to traditional biotech companies that rely solely on product sales.
• The company's gross margin of 86% is strong compared to many biotech companies, reflecting the premium pricing of its technology.
• The company's continued net losses are typical for a growth-stage biotech company investing heavily in R&D and commercial expansion.
• Compared to companies like CRISPR Therapeutics and Editas Medicine, which focus on gene editing, MaxCyte's focus on cell engineering and delivery provides a different value proposition.
• The company's reliance on strategic partnerships is similar to companies like BioNTech, which have leveraged partnerships to accelerate the development and commercialization of their technologies.
• MaxCyte's technology is used by one of its SPL partners to engineer the first ex-vivo cell therapy approved by the FDA in December 2023, demonstrating the clinical validation of its platform.

Related Party Transactions

• The Company entered into a consulting agreement with a member of the Board of Directors for a 12-month period for an amount not to exceed $150.
• The Company sold $83 and $84 in products to a customer whose Chief Executive Officer is a member of the Company's Board of Directors for the three and six months ended June 30, 2024, respectively.
• The Company sold less than $1 in products to a customer whose Board of Directors includes a member who also serves on the Company's Board of Directors for the three and six months ended June 30, 2024.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses, but encouraged by the revenue growth and strategic partnerships.
• Employees may benefit from the company's growth and expansion, but may also face uncertainty due to the company's financial situation.
• Customers will benefit from the company's continued investment in research and development and product development.
• Suppliers may see increased demand for their products as the company scales its manufacturing operations.
• Creditors may be concerned about the company's accumulated deficit and potential need for additional financing.

Next Steps

• The company will continue to focus on growing commercial sales of its products in both the U.S. and international markets.
• The company will continue to grow its sales force, scale its manufacturing operations, and continue research and development efforts to develop new products and further enhance existing products.
• The company will continue to build on its existing SPL partnerships and develop additional SPL partnerships in the future.

Key Dates

Keywords

cell therapy, electroporation, strategic platform licenses, revenue, biopharmaceutical, gross margin, operating expenses, net loss, disposables, instruments